Pfizer Outlines Postacquisition Manufacturing Strategy

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following its $68-billion acquisition of Wyeth, Pfizer is integrating its manufacturing and outsourcing activities (Podcast).

Following its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) is integrating its manufacturing and outsourcing activities. In a joint podcast with its sister publication BioPharm International, Pharmaceutical Technology discusses Pfizer's plans for manufacturing integration with Tony Maddaluna, senior vice-president of strategy and supply-network transformation at Pfizer Global Manufacturing. The podcast is moderated by Laura Bush, editor-in-chief of BioPharm International

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content